Critical Review of the Current and Future Challenges Associated with Advanced in Vitro Systems Towards the Study of Nanoparticle (secondary) Genotoxicity

Overview

Journal Mutagenesis

Publisher Oxford University Press

Specialties Environmental Health
Genetics

Date 2016 Nov 6

PMID 27815329

Citations 35

Authors

Stephen J Evans

Martin J D Clift

Neenu Singh

Jefferson de Oliveira Mallia

Michael Burgum

John W Wills

Thomas S Wilkinson

Gareth J S Jenkins

Shareen H Doak

Affiliations

Soon will be listed here.

Abstract

With the need to understand the potential biological impact of the plethora of nanoparticles (NPs) being manufactured for a wide range of potential human applications, due to their inevitable human exposure, research activities in the field of NP toxicology has grown exponentially over the last decade. Whilst such increased research efforts have elucidated an increasingly significant knowledge base pertaining to the potential human health hazard posed by NPs, understanding regarding the possibility for NPs to elicit genotoxicity is limited. In vivo models are unable to adequately discriminate between the specific modes of action associated with the onset of genotoxicity. Additionally, in line with the recent European directives, there is an inherent need to move away from invasive animal testing strategies. Thus, in vitro systems are an important tool for expanding our mechanistic insight into NP genotoxicity. Yet uncertainty remains concerning their validity and specificity for this purpose due to the unique challenges presented when correlating NP behaviour in vitro and in vivo This review therefore highlights the current state of the art in advanced in vitro systems and their specific advantages and disadvantages from a NP genotoxicity testing perspective. Key indicators will be given related to how these systems might be used or improved to enhance understanding of NP genotoxicity.

Citing Articles

Nanotechnology in healthcare, and its safety and environmental risks.

Ma X, Tian Y, Yang R, Wang H, Allahou L, Chang J J Nanobiotechnology. 2024; 22(1):715.

PMID: 39548502 PMC: 11566612. DOI: 10.1186/s12951-024-02901-x.

Adapting the in vitro micronucleus assay (OECD Test Guideline No. 487) for testing of manufactured nanomaterials: recommendations for best practices.

Burgum M, Ulrich C, Partosa N, Evans S, Gomes C, Seiffert S Mutagenesis. 2024; 39(3):205-217.

PMID: 38502821 PMC: 11040148. DOI: 10.1093/mutage/geae010.

The Growing Importance of Three-Dimensional Models and Microphysiological Systems in the Assessment of Mycotoxin Toxicity.

Zingales V, Esposito M, Torriero N, Taroncher M, Cimetta E, Ruiz M Toxins (Basel). 2023; 15(7).

PMID: 37505691 PMC: 10467068. DOI: 10.3390/toxins15070422.

Current status and future challenges of genotoxicity OECD Test Guidelines for nanomaterials: a workshop report.

Doak S, Andreoli C, Burgum M, Chaudhry Q, Bleeker E, Bossa C Mutagenesis. 2023; 38(4):183-191.

PMID: 37234002 PMC: 10448853. DOI: 10.1093/mutage/gead017.

The State of the Art and Challenges of In Vitro Methods for Human Hazard Assessment of Nanomaterials in the Context of Safe-by-Design.

Ruijter N, Soeteman-Hernandez L, Carriere M, Boyles M, McLean P, Catalan J Nanomaterials (Basel). 2023; 13(3).

PMID: 36770432 PMC: 9920318. DOI: 10.3390/nano13030472.

References

Clift M, Endes C, Vanhecke D, Wick P, Gehr P, Schins R . A comparative study of different in vitro lung cell culture systems to assess the most beneficial tool for screening the potential adverse effects of carbon nanotubes. Toxicol Sci. 2013; 137(1):55-64. DOI: 10.1093/toxsci/kft216. View

Clift M, Gehr P, Rothen-Rutishauser B . Nanotoxicology: a perspective and discussion of whether or not in vitro testing is a valid alternative. Arch Toxicol. 2010; 85(7):723-31. DOI: 10.1007/s00204-010-0560-6. View

Arora S, Rajwade J, Paknikar K . Nanotoxicology and in vitro studies: the need of the hour. Toxicol Appl Pharmacol. 2011; 258(2):151-65. DOI: 10.1016/j.taap.2011.11.010. View

Aardema M, Barnett B, Khambatta Z, Reisinger K, Ouedraogo-Arras G, Faquet B . International prevalidation studies of the EpiDerm 3D human reconstructed skin micronucleus (RSMN) assay: transferability and reproducibility. Mutat Res. 2010; 701(2):123-31. DOI: 10.1016/j.mrgentox.2010.05.017. View

Magdolenova Z, Collins A, Kumar A, Dhawan A, Stone V, Dusinska M . Mechanisms of genotoxicity. A review of in vitro and in vivo studies with engineered nanoparticles. Nanotoxicology. 2013; 8(3):233-78. DOI: 10.3109/17435390.2013.773464. View

Lee J, Lilly G, Doty R, Podsiadlo P, Kotov N . In vitro toxicity testing of nanoparticles in 3D cell culture. Small. 2009; 5(10):1213-21. DOI: 10.1002/smll.200801788. View

Foldbjerg R, Dang D, Autrup H . Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549. Arch Toxicol. 2010; 85(7):743-50. DOI: 10.1007/s00204-010-0545-5. View

Kermanizadeh A, Gaiser B, Johnston H, Brown D, Stone V . Toxicological effect of engineered nanomaterials on the liver. Br J Pharmacol. 2013; 171(17):3980-7. PMC: 4243972. DOI: 10.1111/bph.12421. View

Manshian B, Jenkins G, Williams P, Wright C, Barron A, Brown A . Single-walled carbon nanotubes: differential genotoxic potential associated with physico-chemical properties. Nanotoxicology. 2012; 7(2):144-56. DOI: 10.3109/17435390.2011.647928. View

10.

Cozens A, Yezzi M, Kunzelmann K, Ohrui T, Chin L, Eng K . CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. Am J Respir Cell Mol Biol. 1994; 10(1):38-47. DOI: 10.1165/ajrcmb.10.1.7507342. View

11.

Muller L, Riediker M, Wick P, Mohr M, Gehr P, Rothen-Rutishauser B . Oxidative stress and inflammation response after nanoparticle exposure: differences between human lung cell monocultures and an advanced three-dimensional model of the human epithelial airways. J R Soc Interface. 2009; 7 Suppl 1:S27-40. PMC: 2843981. DOI: 10.1098/rsif.2009.0161.focus. View

12.

Choi J, Kim H, Choi J, Oh S, Park J, Park K . Skin corrosion and irritation test of sunscreen nanoparticles using reconstructed 3D human skin model. Environ Health Toxicol. 2014; 29:e2014004. PMC: 4152941. DOI: 10.5620/eht.2014.29.e2014004. View

13.

Jantzen K, Roursgaard M, Desler C, Loft S, Rasmussen L, Moller P . Oxidative damage to DNA by diesel exhaust particle exposure in co-cultures of human lung epithelial cells and macrophages. Mutagenesis. 2012; 27(6):693-701. DOI: 10.1093/mutage/ges035. View

14.

Bryce S, Shi J, Nicolette J, Diehl M, Sonders P, Avlasevich S . High content flow cytometric micronucleus scoring method is applicable to attachment cell lines. Environ Mol Mutagen. 2009; 51(3):260-6. PMC: 2841230. DOI: 10.1002/em.20544. View

15.

Ghosh M, J M, Sinha S, Chakraborty A, Mallick S, Bandyopadhyay M . In vitro and in vivo genotoxicity of silver nanoparticles. Mutat Res. 2012; 749(1-2):60-9. DOI: 10.1016/j.mrgentox.2012.08.007. View

16.

Burden N, Aschberger K, Chaudhry Q, Clift M, Fowler P, Johnston H . Aligning nanotoxicology with the 3Rs: What is needed to realise the short, medium and long-term opportunities?. Regul Toxicol Pharmacol. 2017; 91:257-266. DOI: 10.1016/j.yrtph.2017.10.021. View

17.

Monteiller C, Tran L, MacNee W, Faux S, Jones A, Miller B . The pro-inflammatory effects of low-toxicity low-solubility particles, nanoparticles and fine particles, on epithelial cells in vitro: the role of surface area. Occup Environ Med. 2007; 64(9):609-15. PMC: 2092561. DOI: 10.1136/oem.2005.024802. View

18.

Roy R, Kumar S, Tripathi A, Das M, Dwivedi P . Interactive threats of nanoparticles to the biological system. Immunol Lett. 2013; 158(1-2):79-87. DOI: 10.1016/j.imlet.2013.11.019. View

19.

Rothen-Rutishauser B, Blank F, Muhlfeld C, Gehr P . In vitro models of the human epithelial airway barrier to study the toxic potential of particulate matter. Expert Opin Drug Metab Toxicol. 2008; 4(8):1075-89. DOI: 10.1517/17425255.4.8.1075. View

20.

Doak S, Manshian B, Jenkins G, Singh N . In vitro genotoxicity testing strategy for nanomaterials and the adaptation of current OECD guidelines. Mutat Res. 2011; 745(1-2):104-11. PMC: 4028084. DOI: 10.1016/j.mrgentox.2011.09.013. View